Regentis Biomaterials LTD 20-F annual reports
The annual report filed by foreign private issuers listed on a US exchange — the 10-K’s equivalent for non-US companies.
AMEX
Regentis Biomaterials Ltd. filed an amended annual report for 2025, revealing a significant increase in net loss to $13.6 million and continued doubt about its ability to continue as a going concern, despite a $10 million IPO.
AMEX
Regentis Biomaterials reported a significant net loss in 2025, driven by increased administrative costs and financial expenses, while advancing its pivotal GelrinC clinical trial and securing IPO funding.